Management of Autoimmune Disease

Initial Assessment and Treatment

The primary goal in managing autoimmune disease is to decrease inflammation, minimize symptoms, and prevent disease progression through immunosuppressive therapy, with corticosteroids serving as the mainstay for acute flares and disease-modifying agents for long-term control, as recommended by the American Association for the Study of Liver Diseases and the American Society of Clinical Oncology 1, 2
Perform comprehensive evaluation including disease activity markers and organ involvement assessment to determine severity and guide treatment intensity, according to the European Association for the Study of the Liver 3
Baseline immunologic workup including autoantibody profiles, immunoglobulin levels, and inflammatory markers is essential for determining the severity of autoimmune disease, as suggested by the American Association for the Study of Liver Diseases and the American Academy of Allergy, Asthma, and Immunology 1, 4
Screen for concurrent infections including viral hepatitis, HIV, tuberculosis, and other opportunistic pathogens that may be unmasked by immune modulation, as recommended by the European Society for Medical Oncology 5
Document all co-medications as antiarrhythmics, antihypertensives, antibiotics, anticonvulsants, and antipsychotics can potentiate autoimmunity, according to the European Society for Medical Oncology 5

All patients with active autoimmune disease should receive immunosuppressive treatment to prevent progression and organ damage, as recommended by the American Association for the Study of Liver Diseases 1
Corticosteroids are first-line therapy for acute flares, with prednisone typically started at 30-60 mg/day and tapered based on response, according to the American Society of Clinical Oncology and the American Association for the Study of Liver Diseases 1, 2
Combination therapy with prednisone plus azathioprine is preferred over monotherapy as it provides similar efficacy with fewer side effects, as suggested by the American Association for the Study of Liver Diseases 1
For severe flares with major organ involvement, initiate high-dose corticosteroids immediately and consider hospitalization, as recommended by the American Society of Clinical Oncology and the European Association for the Study of the Liver 2, 3

Educate patients that autoimmune adverse reactions can occur at any time—at the beginning, during, or after treatment discontinuation—and early detection is essential to limit severity, as recommended by the European Society for Medical Oncology 5
Monitor complete blood count regularly to detect thrombocytopenia, anemia, leukopenia, or lymphopenia, according to the American College of Medical Genetics and Genomics and the European Association for the Study of the Liver 7, 3
Screen for autoimmune thyroid disease routinely as it commonly coexists with other autoimmune conditions, as suggested by the American College of Medical Genetics and Genomics 7

Inflammatory arthritis symptoms include joint pain with swelling and morning stiffness >30-60 minutes, according to the American College of Rheumatology 2
Myositis presents with muscle pain and weakness and can be life-threatening if respiratory muscles or myocardium are involved, as recommended by the American College of Rheumatology 2
New-onset hyperglycemia without risk factors for type 2 diabetes should raise concern for checkpoint inhibitor-associated diabetes mellitus, according to the American Society of Clinical Oncology 2

Failing to distinguish between autoimmune disease flare and treatment-related adverse events, which may present with similar symptoms, as recommended by the European Association for the Study of the Liver 3
Overlooking the increased risk of infection in patients on immunosuppressants, according to the European Association for the Study of the Liver 3
Ignoring the progressive nature of autoimmune disease even when symptoms appear mild, as recommended by the American Association for the Study of Liver Diseases 1